Drug delivery platform will release medication for monthly dosing
August 30, 2019
Although lowering side effects plays an important role in oral contraceptive compliance, one of the biggest challenges for patients is adhering to the daily schedule of the pill. Forgetting one to three pills per cycle is a frequent problem among 15-51% of users, particularly among adolescents. Lyndra Therapeutics has received a $13 million grant from the Bill & Melinda Gates Foundation and is setting out to remove the daily pill compliance challenge. The company is in early development of a monthly oral contraceptive to provide women with a discreet, noninvasive, reversible contraception option.
Despite guidance stating that a patient should be offered the option to begin her chosen long-acting reversible contraception birth control method at the time of the office visit rather than waiting for her next period or returning for another appointment, just 29% of clinicians say they provide same-day placement.
In 2002, just 2.4% of U.S. women using birth control were using long-acting reversible contraceptive (LARC) methods, such as the intrauterine device or the contraceptive implant. By 2014, about 14% of women using birth control reported LARC use.
Immediate postpartum placement offers safe, effective birth control
May 25, 2018
The American College of Obstetricians and Gynecologists now recognizes immediate postpartum placement of either the intrauterine device or the contraceptive implant as a best practice because of the long-acting reversible contraceptive methods’ role in preventing rapid repeat and unintended pregnancy
Four-hour training session affects providers’ attitudes, knowledge, and practices
April 26, 2018
Research from the Bixby Center for Global Reproductive Health at the University of California, San Francisco, and Planned Parenthood Federation of America indicates that a four-hour training intervention can significantly affect the likelihood that healthcare providers will integrate long-acting reversible contraceptives into their clinical care.
The success of the Contraceptive CHOICE Project in removing financial barriers to contraception, promoting the most effective methods of birth control, and reducing unintended pregnancy is no longer an isolated event.
Four-year data from the ongoing multicenter, U.S.-based pivotal trial of the 52 mg Liletta levonorgestrel-releasing intrauterine device (IUD) indicate its safety and efficacy for four years of use in nulliparous and parous women, as well as in non-obese and obese women.